Our proposed genomic assay, ImPrint, captures more comprehensive immune activity status to permit more effective selection of IO-sensitive ER+HER2– cancers, as the ImPrint+ cancers have a 75% pCR rate with neoadjuvant IO therapy. Here, ERBB2 is linked to cancer.